Lipella Pharmaceuticals Inc(LIPO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LIPO Lipella Pharmaceuticals Inc

Market Closed 02-14 16:00:00 EST

3.88

-0.14

-3.48%

盘后4.02

+0.14+3.61%

19:59 EST

High4.14	Low3.69	Vol217.99K
Open4.14	D1 Closing4.02	Amplitude11.19%
Mkt Cap4.69M	Tradable Cap3.31M	Total Shares1.21M
T/O850.81K	T/O Rate25.53%	Tradable Shares853.80K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LIPO","market":"US","secType":"STK","nameCN":"Lipella Pharmaceuticals Inc","latestPrice":3.88,"timestamp":1739566800000,"preClose":4.02,"halted":0,"volume":217990,"hourTrading":{"tag":"盘后","latestPrice":4.02,"preClose":3.88,"latestTime":"19:59 EST","volume":3722,"amount":14666.7429,"timestamp":1739581163897},"delay":0,"floatShares":853801,"shares":1208919,"eps":-4.462692,"marketStatus":"Market Closed","change":-0.14,"latestTime":"02-14 16:00:00 EST","open":4.14,"high":4.14,"low":3.69,"amount":850808.9752750001,"amplitude":0.11194,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.462692,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"listingDate":1671512400000,"exchange":"NASDAQ","adjPreClose":4.02,"preHourTrading":{"tag":"盘前","latestPrice":4.18,"preClose":4.02,"latestTime":"09:28 EST","volume":4783,"amount":19749.308329000003,"timestamp":1739543289479},"postHourTrading":{"tag":"盘后","latestPrice":4.02,"preClose":3.88,"latestTime":"19:59 EST","volume":3722,"amount":14666.7429,"timestamp":1739581163897},"volumeRatio":0.02453607580880826},"requestUrl":"/m/hq/s/LIPO/tweets","defaultTab":"tweets","newsList":[{"id":"2510540763","title":"Sector Update: Health Care Stocks Fall in Late Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2510540763","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510540763?lang=en_us&edition=fundamental","pubTime":"2025-02-12 04:56","pubTimestamp":1739307384,"startTime":"0","endTime":"0","summary":"Health care stocks were down  late Tuesday afternoon with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund  shedding 0.1%.The iShares Biotechnology ETF  fell 1.4%.In corporate news, Travere Therapeutics  shares rose 13% after the company said it completed a meeting with the US Food and Drug Administration and plans to submit a supplemental new drug application for approval of Filspari as a potential treatment for focal segmental glomerulosclerosis, a rare kidney disorder.Firefly Neuroscience  shares surged 174% after it said it was accepted into Nvidia's  Connect program.Novartis  agreed to buy biopharmaceutical firm Anthos Therapeutics for up to $3.1 billion as the Swiss pharmaceutical giant expands its cardiovascular portfolio. Novartis shares added 0.8%.Lipella Pharmaceuticals  shares jumped 35% after it reported positive topline results from a phase 2a trial of LP-310, a liposomal-tacrolimus oral rinse for oral lichen planus.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2326559502.SGD","BK4581","BK4167","LU0861579265.USD","NVD3.UK","LU0289960550.SGD","NVD2.UK","NVS","NVDY","SG9999001424.SGD","SNVD.UK","LU0211331839.USD","LU0642271901.SGD","TVTX","LU2125154778.USD","NVDX","IE00B19Z8X17.USD","NVIW.SI","NVDS.UK","IE00BFSS7M15.SGD","LU2361044949.HKD","NVDU","NVDD","LIPO","LU1815336760.USD","LU1244550577.SGD","NVDA","LU1280957306.USD","LU2592432038.USD","SGXZ51526630.SGD","2NVD.UK","3NVD.UK","LU2360032135.SGD","BK4548","LU0320765059.SGD","LU0868494708.USD","LU2125909759.SGD","LU0672654240.SGD","LU1951200564.SGD","LU2471134952.CNY","XLV","LU1066051498.USD","NVDS","IBB","NVD","SG9999015978.USD","LU1935042991.SGD","LU0069063385.USD","AIFF"],"gpt_icon":1},{"id":"2510353188","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2510353188","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510353188?lang=en_us&edition=fundamental","pubTime":"2025-02-12 02:34","pubTimestamp":1739298847,"startTime":"0","endTime":"0","summary":"Firefly Neuroscience  shares were up more than 170% in recent trading after the company said it was accepted into the Nvidia  Connect program.Intraday trading volume catapulted to over 155 million shares from a daily average of about 2.48 million.Lipella Pharmaceuticals  said its treatment candidate for oral lichen planus showed \"clinically meaningful\" reductions in pain, ulceration, and inflammation across all key metrics in a phase 2a trial.Shares soared about 36% as intraday trading volume surged to over 37.2 million from a daily average of about 1.59 million.Travere Therapeutics  said it completed a meeting with the US Food and Drug Administration and plans to submit a supplemental new drug application for approval of Filspari for focal segmental glomerulosclerosis, a rare kidney disorder.Wedbush raised its price target on the stock to $30 from $26 while maintaining its outperform rating.Shares of Travere rose 13% as intraday trading volume climbed to over 3.62 million from a daily","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0528227936.USD","LU2430703095.HKD","LU0048584097.USD","LU0345768153.USD","LU2430703178.SGD","NVDS.UK","IE00B3M56506.USD","SG9999002232.USD","BK4608","LU0965509283.SGD","LU1935042991.SGD","LU1674673428.USD","3NVD.UK","NVD","NVDA","AIFF","TVTX","SNVD.UK","LIPO","LU1720051017.SGD","LU2750360641.GBP","LU1429558221.USD","LU0096362180.USD","LU2265009873.SGD","LU2505996681.GBP","LU1642822529.SGD","NVDY","LU2242650005.HKD","2NVD.UK","NVD2.UK","LU0069063385.USD","IE00BK4W5M84.HKD","IE00BYXW3230.USD","NVDU","LU1037948541.HKD","LU1280957306.USD","LU2461242641.AUD","BK4554","NVD3.UK","BK4598","HK0000306701.USD","NVDS","NVDD","LU0107464264.USD","NVDX","LU0072462426.USD","LU0417517546.SGD","LU2357125470.USD","NVIW.SI"],"gpt_icon":1},{"id":"2510589363","title":"Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2510589363","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510589363?lang=en_us&edition=fundamental","pubTime":"2025-02-12 02:10","pubTimestamp":1739297401,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals' (LIPO) shares jumped nearly 35% in recent Tuesday trading after the company reported positive topline results from its phase 2a multicenter dose-ranging trial of LP-310, a lip","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2510133026","title":"Lipella Pharma Shares Rise After Positive Trial Data for Oral Lichen Planus Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2510133026","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510133026?lang=en_us&edition=fundamental","pubTime":"2025-02-12 01:56","pubTimestamp":1739296560,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals shares were up 37% to $4.18 after the company said it saw positive topline results from its Phase 2a dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus.The biotechnology company said LP-310 demonstrated a strong safety profile, with no product-related serious adverse events and no patient dropouts.Oral lichen planus is a chronic inflammatory condition that affects the mucous membranes inside the mouth, on the tongue, cheeks, gums or palate.The trial showed statistically significant improvements across multiple patient-reported and investigator-measured efficacy endpoints at weeks one, four and six, Lipella said.The trial, which is active across seven U.S. sites, has progressed to the next higher dose cohort of 0.5 mg/10 mL.Lipella continues to recruit for the trial, with plans to activate additional sites and complete the trial by mid-2025. The company is preparing for key miles","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2510339585","title":"Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes","url":"https://stock-news.laohu8.com/highlight/detail?id=2510339585","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510339585?lang=en_us&edition=fundamental","pubTime":"2025-02-11 23:52","pubTimestamp":1739289156,"startTime":"0","endTime":"0","summary":"On Tuesday, Lipella Pharmaceuticals Inc.  shared topline an analysis of its Phase 2a dose-ranging trial of LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus .LP-310 demonstrated a strong safety profile, with no product-related serious adverse events  or patient dropouts.The trial showed statistically significant improvements across multiple patient-reported and investigator-measured efficacy endpoints at weeks 1, 4, and 6.LP-310 is the only oral rinse topical treatment currently in development for OLP.Affecting about 6 million Americans, OLP is a chronic inflammatory condition that targets mucous membranes in the mouth, which can cause pain and make eating, drinking, and even speaking uncomfortable.Characterized by symptoms such as burning pain, white patches, swollen tissue and open sores, OLP has no FDA-approved therapies.The trial showed significant improvements across multiple efficacy endpoints while suggesting the safety an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nano-cap-lipella-pharmaceuticals-stock-155236668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4160","BK4139","LIPO","OLP"],"gpt_icon":0},{"id":"2510876413","title":"BUZZ-U.S. STOCKS ON THE MOVE-Humana, S&P Global, Charles Schwab","url":"https://stock-news.laohu8.com/highlight/detail?id=2510876413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510876413?lang=en_us&edition=fundamental","pubTime":"2025-02-11 22:34","pubTimestamp":1739284491,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Humana, S&P Global, Charles SchwabEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nL6N3P209D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0742537680.HKD","MAR","ALB","PSX","BK4516","BK4535","LU1989773731.SGD","LU2023251221.USD","SG9999015358.SGD","LU2237443549.SGD","CRNX","IE00BLSP4452.SGD","LU0158827948.USD","LU0342679015.USD","LU1496350502.SGD","GFS","KO","BK4142","LU0208291251.USD","X","IE00B64PRP62.GBP","KLG","PLYA","STLD","SCHW","BLK","BK4597","SG9999014567.USD","IE00B42XCP33.USD","CENX","BK4589","IE00B19Z9505.USD","HE","LIPO","BK4534","HUM","SG9999002232.USD","FIS","LU0949170772.SGD","LDOS","LU2023250504.SGD","HESM","SPGI","LU1868837136.USD","NUE","LU1670710588.SGD","SG9999014013.SGD","LU0170899867.USD","HYPR","HUBS"],"gpt_icon":1},{"id":"2510382002","title":"Lipella Pharmaceuticals Shares up 41.9% After Inflammatory Disease Drug Found Safe in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2510382002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510382002?lang=en_us&edition=fundamental","pubTime":"2025-02-11 22:32","pubTimestamp":1739284332,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P211L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2510800929","title":"BUZZ-U.S. STOCKS ON THE MOVE-Phillips 66,  Coca-Cola, Leidos","url":"https://stock-news.laohu8.com/highlight/detail?id=2510800929","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510800929?lang=en_us&edition=fundamental","pubTime":"2025-02-11 20:11","pubTimestamp":1739275901,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Phillips 66, Coca-Cola, LeidosEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nL6N3P20EC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836591.USD","PSX","BK4585","BK4516","BK4533","IE00B3PB1722.GBP","LU1670711123.USD","BK4581","LU0098860793.USD","LU0795875086.SGD","LU2506952097.USD","BK4139","LU2237443382.USD","LU1868837300.USD","LU2237443978.SGD","KO","LU2506951875.HKD","LU1670711040.USD","X","LU0950375773.USD","LU2237957902.USD","LU2125154935.USD","STLD","BK4520","SG9999014567.USD","IE00B42XCP33.USD","LU1162221912.USD","CENX","IE00BVYPNV92.GBP","HE","IE00BSNM7G36.USD","LIPO","LU0330918003.SGD","LU0061474960.USD","LU2506952170.USD","SG9999002232.USD","LDOS","LU2133065610.SGD","LU1221951046.USD","LU0912757837.SGD","IE00BDGV0183.EUR","LU0006061336.USD","LU1116320737.USD","LU1868837136.USD","LU1894683264.USD","NUE","LU0170899867.USD","LU1732799900.SGD","LU2237443622.USD","HUBS"],"gpt_icon":1},{"id":"2510334807","title":"BUZZ-Lipella jumps after inflammatory disease drug found safe in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2510334807","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510334807?lang=en_us&edition=fundamental","pubTime":"2025-02-11 19:50","pubTimestamp":1739274624,"startTime":"0","endTime":"0","summary":"BUZZ-Lipella jumps after inflammatory disease drug found safe in study ** Shares of Pittsburgh-based drug developer Lipella Pharmaceuticals LIPO.O rise 68.20% to $5.14 premarket ** LIPO says its exper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nL4N3P20OK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2510880971","title":"Lipella Pharmaceuticals Inc - Lp-310 Shows Clinically Meaningful Reductions in Pain, Ulceration, Inflammation","url":"https://stock-news.laohu8.com/highlight/detail?id=2510880971","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510880971?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:46","pubTimestamp":1739270812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P11GN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2510809759","title":"Lipella Pharmaceuticals Inc - to Submit Phase 2B Ind Application and Breakthrough Therapy Request in H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2510809759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510809759?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:46","pubTimestamp":1739270812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P11GN:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2510780929","title":"Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for Lp-310 in the Treatment of Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2510780929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510780929?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:46","pubTimestamp":1739270812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P11GN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2510218809","title":"Lipella Pharmaceuticals Inc - Lp-310 Shows Strong Safety Profile, No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2510218809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510218809?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:46","pubTimestamp":1739270812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P11GN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2509005322","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2509005322","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509005322?lang=en_us&edition=fundamental","pubTime":"2025-02-07 02:43","pubTimestamp":1738867391,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals  shares soared 79% after the company said Thursday it received a US Food and Drug Administration approval for an expanded access program for LP-310, an oral rinse formulation designed to treat oral lichen planus.Over 82.1 million shares traded intraday versus a daily average of roughly 127,000.TransCode Therapeutics  said Thursday that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The dose administered to patients in the cohort was about double that of Cohort 2.Shares jumped nearly 33% as intraday trading volume climbed to more than 11.7 million from a daily average of over 1.44 million.Tapestry  reported Thursday higher fiscal Q2 non-GAAP earnings and net sales while raising its outlook for fiscal 2025.Shares rose roughly 13%, with intraday trading volume rising to nearly 10.6 million, compared with a daily average of more than 4.87 million.Price: 4.69, Change: +2.07, Percent Change: +","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4516","BK4202","RNAZ","LU0052756011.USD","BK4139","BK4539","LU0070302665.USD","LU0310800965.SGD","LU1267930227.SGD","TPR","BK4585","LU0128525689.USD","LU0208291251.USD","BK4588","LU0320765489.SGD","LIPO"],"gpt_icon":0},{"id":"2509277765","title":"Dow Edges Higher; US Weekly Jobless Claims Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2509277765","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509277765?lang=en_us&edition=fundamental","pubTime":"2025-02-06 23:06","pubTimestamp":1738854417,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d692b68f53e736a66ee6c4966456b3a5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/43531523/dow-edges-higher-us-weekly-jobless-claims-increase","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","NVIW.SI","NQmain","BK4585","SQQQ","SRTS","USJW.SI","PSQ","RETO","MNQmain","BK4007","QNTM","BK4082","BK4023","BK4011",".IXIC","BK4588","QID","APPS","LIPO","AVGR","BK4139","TSYW.SI","USAW.SI","TQQQ"],"gpt_icon":1},{"id":"2509052279","title":"Investor Sentiment Muted Amid Earnings Deluge, Stifling US Equity Futures Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2509052279","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509052279?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:05","pubTimestamp":1738850748,"startTime":"0","endTime":"0","summary":"US equity futures were flat ahead of Thursday's opening bell as traders digested a deluge of corporate earnings.The Dow Jones Industrial Average futures increased 0.1%, S&P 500 futures gained 0.1%, wh","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SWKS",".IXIC","RBLX","AMZN","LIPO","EQR","PM",".SPX","LLY",".DJI","MTRX"],"gpt_icon":1},{"id":"2509225720","title":"Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for Lp-310 in Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2509225720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509225720?lang=en_us&edition=fundamental","pubTime":"2025-02-06 19:00","pubTimestamp":1738839600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA6BMPB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2509998226","title":"Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2509998226","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509998226?lang=en_us&edition=fundamental","pubTime":"2025-02-06 19:00","pubTimestamp":1738839600,"startTime":"0","endTime":"0","summary":"PITTSBURGH, Feb. 06, 2025  -- Lipella Pharmaceuticals Inc.  , a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration  has granted approval for an Expanded Access Program  for LP-310, an oral rinse formulation designed to treat oral lichen planus .LP-310 is an innovative, localized therapy formulated to provide targeted relief for OLP patients while minimizing systemic exposure. Oral lichen planus is a chronic inflammatory condition affecting the mucous membranes inside the mouth, often causing burning pain, white patches, swollen tissue and open sores. The condition impacts approximately 6 million Americans and currently has no FDA-approved therapies.Forward-Looking StatementsThis press release includes certain \"forward-looking statements.\" All statements, other than statements of historical fact, included in this press release regarding, among other things,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipella-pharmaceuticals-granted-fda-approval-110000849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LIPO","OLP","BK4160","BK4139"],"gpt_icon":0},{"id":"2502180358","title":"Spartan Capital Securities, Llc Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2502180358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502180358?lang=en_us&edition=fundamental","pubTime":"2025-01-11 02:24","pubTimestamp":1736533478,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUAYS0Z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2502138658","title":"Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2502138658","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502138658?lang=en_us&edition=fundamental","pubTime":"2025-01-11 02:24","pubTimestamp":1736533440,"startTime":"0","endTime":"0","summary":"New York, NY, Jan. 10, 2025  -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of two private placements for Lipella Pharmaceuticals Inc. . Spartan Capital Securities, LLC acted as the sole placement agent in these private offerings of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc., raising an aggregate total of $875,500 through the transactions.“We are proud to serve as the sole placement agent in these private placements for Lipella Pharmaceuticals,” said John Lowry, CEO of Spartan Capital Securities. “Lipella’s dedication to developing innovative therapies aimed at improving patient outcomes is inspiring. These successful transactions reflect both the strength of Lipella’s clinical pipeline and Spartan Capital’s commitment to facilitating impactful investment opportunities. We look forward to supporting Lipella’s future growth and success.”Spartan Capital Securities, LLC is a premi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spartan-capital-securities-llc-serves-182400686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPAQ.U","BK4139","LIPO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lipella.com","stockEarnings":[{"period":"1week","weight":0.2638},{"period":"1month","weight":0.2977},{"period":"3month","weight":0.5987},{"period":"6month","weight":0.2125},{"period":"1year","weight":-0.515},{"period":"ytd","weight":0.2721}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.","exchange":"NASDAQ","name":"Lipella Pharmaceuticals Inc","nameEN":"Lipella Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lipella Pharmaceuticals Inc(LIPO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lipella Pharmaceuticals Inc(LIPO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lipella Pharmaceuticals Inc,LIPO,Lipella Pharmaceuticals Inc股票,Lipella Pharmaceuticals Inc股票老虎,Lipella Pharmaceuticals Inc股票老虎国际,Lipella Pharmaceuticals Inc行情,Lipella Pharmaceuticals Inc股票行情,Lipella Pharmaceuticals Inc股价,Lipella Pharmaceuticals Inc股市,Lipella Pharmaceuticals Inc股票价格,Lipella Pharmaceuticals Inc股票交易,Lipella Pharmaceuticals Inc股票购买,Lipella Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lipella Pharmaceuticals Inc(LIPO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lipella Pharmaceuticals Inc(LIPO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction